Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study
- 23 May 2006
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 58 (5-6), 723-734
- https://doi.org/10.1016/j.addr.2006.05.003
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragmentsNuclear Medicine and Biology, 2005
- Rituximab-Dependent Cytotoxicity by Natural Killer CellsCancer Research, 2004
- RTCGD: retroviral tagged cancer gene databaseNucleic Acids Research, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cellsOncogene, 2002
- Ig-binding Receptors on Human NK Cells as Effector and Regulatory Surface MoleculesInternational Reviews of Immunology, 2001
- Bispecific HER2 × CD3 Antibodies Enhance T-Cell Cytotoxicity in Vitro and Localize to HER2-Overexpressing Xenografts in Nude MiceClinical Immunology and Immunopathology, 1995
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987